Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib Dose Escalation in Refractory Axial Spondyloarthritis
NCT06310057Phase 4Completed
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Jan 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tofacitinib in axial spondyloarthritis (axSpA), sponsored by Bangabandhu Sheikh Mujib Medical University. Started Jan 2022; status: completed.
02
Drugs
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT06310057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310057.